Tisagenlecleucel for relapsed or refractory B-cell acute lymphoblastic leukaemia

Published on 01 Aug 2024
Last Updated on 01 Aug 2024

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended:

• Tisagenlecleucel cells dispersion for infusion for treating patients between two to 25 years of age (both ages inclusive) with B-cell acute lymphoblastic leukaemia that is refractory, in relapse post-transplant or in second or later relapse.

Funding status

Tisagenlecleucel cells dispersion for infusion is recommended for inclusion on the MOH Cell, Tissue and Gene Therapy Product (CTGTP) List for the abovementioned indication from 1 August 2024.

Tisagenlecleucel should be used in line with the additional clinical criteria listed in the Annex.

Tisagenlecleucel for relapsed or refractory B-cell acute lymphoblastic leukaemia (1 Aug 24) [PDF, 207 KB]

PES Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia (1 Aug 24) [PDF, 98 KB]